{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:35:02Z","timestamp":1793504102468,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004286","name":"Santen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004286","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We conducted a retrospective observational cohort study using a nationwide claims database (JMDC database) to investigate the treatment persistence of antiglaucoma ophthalmic solution monotherapy. Patients aged 18 years or older who were diagnosed with glaucoma between November 2018 and August 2020, and prescribed omidenepag isopropyl (OMDI), prostaglandin F receptor agonists (FP), or beta-blockers (BB) monotherapies were included. A total of 36,450 patients (5,865 patients prescribed OMDI, 20,715 patients prescribed FP, and 9,870 patients prescribed BB) were analyzed. The cumulative treatment persistence rate at three years was 27.0% (95% confidence interval [CI]: 25.9\u201328.1) in patients prescribed OMDI, which was significantly higher than 20.9% (95% CI: 20.4\u201321.5) in those prescribed FP; the hazard ratio was 0.835 (95% CI: 0.806\u20130.865,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001), calculated with the multivariate Cox proportional hazards model. The median duration of treatment persistence, calculated with the Kaplan-Meier methods, was 281 days in those prescribed OMDI, 204 days in those prescribed FP, and 152 days in those prescribed BB; the treatment persistence of OMDI tended to be longer than FP or BB. OMDI had a longer treatment persistence compared to other antiglaucoma ophthalmic solutions in the real-world setting, suggesting that OMDI would be a promising first-line treatment option in the long-term management of glaucoma.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-22758-w","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T13:40:06Z","timestamp":1762436406000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Benefit of omidenepag isopropyl ophthalmic solution in treatment persistence in Japanese patients with glaucoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Kenji","family":"Kashiwagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Fuwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Shii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Miyahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"22758_CR1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10384-022-00970-9","volume":"67","author":"Y Kiuchi","year":"2023","unstructured":"Kiuchi, Y. et al. The Japan glaucoma society guidelines for glaucoma 5th edition. Jpn J. Ophthalmol. 67, 189\u2013254 (2023).","journal-title":"Jpn J. Ophthalmol."},{"key":"22758_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ophtha.2020.10.022","volume":"128","author":"SJ Gedde","year":"2021","unstructured":"Gedde, S. J. et al. Primary Open-Angle glaucoma preferred practice Pattern\u00ae. Ophthalmology 128, 71\u2013150 (2021).","journal-title":"Ophthalmology"},{"issue":"Suppl 1","key":"22758_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bjophthalmol-2021-egsguidelines","volume":"105","author":"European Glaucoma Society","year":"2021","unstructured":"European Glaucoma Society Terminology and guidelines for Glaucoma, 5th edition. Br. J. Ophthalmol. 105 (Suppl 1), 1\u2013169 (2021).","journal-title":"Br. J. Ophthalmol."},{"key":"22758_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s10384-018-0623-4","volume":"63","author":"Y Morizane","year":"2019","unstructured":"Morizane, Y. et al. Incidence and causes of visual impairment in japan: the first nation-wide complete enumeration survey of newly certified visually impaired individuals. Jpn J. Ophthalmol. 63, 26\u201333 (2019).","journal-title":"Jpn J. Ophthalmol."},{"key":"22758_CR5","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1001\/jamaophthalmol.2014.3333","volume":"132","author":"D-K Hwang","year":"2014","unstructured":"Hwang, D-K., Liu, C. J. L., Pu, C-Y., Chou, Y-J. & Chou, P. Persistence of topical glaucoma medication a nationwide population-based cohort study in Taiwan. JAMA Ophthalmol. 132, 1446\u20131452 (2014).","journal-title":"JAMA Ophthalmol."},{"issue":"Suppl 1","key":"22758_CR6","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.survophthal.2008.08.002","volume":"53","author":"GF Schwartz","year":"2008","unstructured":"Schwartz, G. F. & Quigley, H. A. Adherence and persistence with glaucoma therapy. Surv. Ophthalmol. 53(Suppl 1), S57\u2013S68 (2008).","journal-title":"Surv. Ophthalmol."},{"key":"22758_CR7","doi-asserted-by":"publisher","first-page":"5052","DOI":"10.1167\/iovs.07-0290","volume":"48","author":"DS Friedman","year":"2007","unstructured":"Friedman, D. S. et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the glaucoma adherence and persistency study (GAPS). Invest. Ophthalmol. Vis. Sci. 48, 5052\u20135057 (2007).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"Suppl","key":"22758_CR8","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.ajo.2003.10.034","volume":"137","author":"GF Schwartz","year":"2004","unstructured":"Schwartz, G. F., Reardon, G. & Mozaffari, E. Persistency with Latanoprost or timolol in primary open-angle glaucoma suspects. Am. J. Ophthalmol. 137(Suppl), S13\u2013S16 (2004).","journal-title":"Am. J. Ophthalmol."},{"key":"22758_CR9","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1007\/s40123-023-00730-z","volume":"12","author":"L Quaranta","year":"2023","unstructured":"Quaranta, L. et al. Adherence and persistence to medical therapy in glaucoma: an overview. Ophthalmol. Ther. 12, 2227\u20132240 (2023).","journal-title":"Ophthalmol. Ther."},{"key":"22758_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s10384-013-0284-2","volume":"58","author":"K Kashiwagi","year":"2014","unstructured":"Kashiwagi, K. & Furuya, T. Persistence with topical glaucoma therapy among newly diagnosed Japanese patients. Jpn J. Ophthalmol. 58, 68\u201374 (2014).","journal-title":"Jpn J. Ophthalmol."},{"key":"22758_CR11","first-page":"347","volume":"110","author":"M Kowal","year":"2008","unstructured":"Kowal, M., Choragiewicz, T., Mietlicka, K., Wyszy\u0144ska, A. & Zarnowski, T. Przyczyny pomijania Zalecanych Dawek lek\u00f3w Przez pacjent\u00f3w z Jaskra [Obstacles to medication compliance for patients with glaucoma]. Klin. Oczna. 110, 347\u2013351 (2008).","journal-title":"Klin. Oczna"},{"key":"22758_CR12","doi-asserted-by":"crossref","unstructured":"The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am. J. Ophthalmol. 130, 429\u2013440. (2000).","DOI":"10.1016\/S0002-9394(00)00538-9"},{"key":"22758_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1517\/14740338.6.1.45","volume":"6","author":"G Holl\u00f3","year":"2007","unstructured":"Holl\u00f3, G. The side effects of the prostaglandin analogues. Expert Opin. Drug Saf. 6, 45\u201352 (2007).","journal-title":"Expert Opin. Drug Saf."},{"issue":"Suppl1","key":"22758_CR14","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1016\/j.survophthal.2008.08.004","volume":"53","author":"A Alm","year":"2008","unstructured":"Alm, A., Grierson, I. & Shields, M. B. Side effects associated with prostaglandin analog therapy. Surv. Ophthalmol. 53 (Suppl1), S93\u2013S105 (2008).","journal-title":"Surv. Ophthalmol."},{"key":"22758_CR15","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.exer.2008.08.022","volume":"88","author":"KP Cracknell","year":"2009","unstructured":"Cracknell, K. P. & Grierson, I. Prostaglandin analogues in the anterior eye: their pressure Lowering action and side effects. Exp. Eye Res. 88, 786\u2013791 (2009).","journal-title":"Exp. Eye Res."},{"key":"22758_CR16","doi-asserted-by":"publisher","first-page":"e26874","DOI":"10.1097\/MD.0000000000026874","volume":"100","author":"M Tanito","year":"2021","unstructured":"Tanito, M. et al. Proposal of a simple grading system integrating cosmetic and tonometric aspects of prostaglandin-associated periorbitopathy. Medicine 100, e26874 (2021).","journal-title":"Medicine"},{"key":"22758_CR17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/08820538.2021.2003824","volume":"37","author":"R Sakata","year":"2022","unstructured":"Sakata, R. et al. Prostaglandin-associated periorbitopathy syndrome (PAPS): addressing an unmet clinical need. Semin Ophthalmol. 37, 447\u2013454 (2022).","journal-title":"Semin Ophthalmol."},{"key":"22758_CR18","doi-asserted-by":"publisher","first-page":"6869","DOI":"10.1021\/acs.jmedchem.8b00808","volume":"61","author":"R Iwamura","year":"2018","unstructured":"Iwamura, R. et al. Identification of a Selective, Non-Prostanoid EP2 receptor agonist for the treatment of glaucoma: omidenepag and its prodrug omidenepag isopropyl. J. Med. Chem. 61, 6869\u20136891 (2018).","journal-title":"J. Med. Chem."},{"key":"22758_CR19","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1089\/jop.2017.0146","volume":"34","author":"M Fuwa","year":"2018","unstructured":"Fuwa, M. et al. Effects of a novel selective EP2 receptor Agonist, omidenepag Isopropyl, on aqueous humor dynamics in Laser-Induced ocular hypertensive monkeys. J. Ocul Pharmacol. Ther. 34, 531\u2013537 (2018).","journal-title":"J. Ocul Pharmacol. Ther."},{"key":"22758_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ajo.2020.06.003","volume":"220","author":"M Aihara","year":"2020","unstructured":"Aihara, M. et al. Omidenepag isopropyl versus Latanoprost in primary Open-Angle glaucoma and ocular hypertension: the phase 3 AYAME study. Am. J. Ophthalmol. 220, 53\u201363 (2020).","journal-title":"Am. J. Ophthalmol."},{"key":"22758_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1089\/jop.2019.0079","volume":"36","author":"Y Yamamoto","year":"2020","unstructured":"Yamamoto, Y. et al. Effects of the selective EP2 receptor agonist omidenepag on adipocyte differentiation in 3T3-L1 cells. J. Ocul Pharmacol. Ther. 36, 162\u2013169 (2020).","journal-title":"J. Ocul Pharmacol. Ther."},{"key":"22758_CR22","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1089\/jop.2020.0003","volume":"36","author":"Y Esaki","year":"2020","unstructured":"Esaki, Y. et al. The antiglaucoma agent and EP2 receptor agonist omidenepag does not affect eyelash growth in mice. J. Ocul Pharmacol. Ther. 36, 529\u2013533 (2020).","journal-title":"J. Ocul Pharmacol. Ther."},{"key":"22758_CR23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10384-021-00855-3","volume":"65","author":"R Sakata","year":"2021","unstructured":"Sakata, R. et al. Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis. Jpn J. Ophthalmol. 65, 591\u2013597 (2021).","journal-title":"Jpn J. Ophthalmol."},{"key":"22758_CR24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ajo.2021.12.011","volume":"237","author":"K Inoue","year":"2022","unstructured":"Inoue, K. et al. Periocular adverse reactions to omidenepag isopropyl. Am. J. Ophthalmol. 237, 114\u2013121 (2022).","journal-title":"Am. J. Ophthalmol."},{"key":"22758_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1089\/jop.2022.0096","volume":"39","author":"R Sakata","year":"2023","unstructured":"Sakata, R. et al. Prostaglandin-Associated periorbitopathy symptom alleviation after switching prostaglandin F receptor agonist to EP2 receptor agonist in patients with glaucoma. J. Ocul Pharmacol. Ther. 39, 63\u201369 (2023).","journal-title":"J. Ocul Pharmacol. Ther."},{"key":"22758_CR26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12886-021-01813-w","volume":"21","author":"C Shirai","year":"2021","unstructured":"Shirai, C., Matsuoka, N. & Nakazawa, T. Comparison of adherence between fixed and unfixed topical combination glaucoma therapies using Japanese healthcare\/pharmacy claims database: a retrospective non-interventional cohort study. BMC Ophthalmol. 21, 52 (2021).","journal-title":"BMC Ophthalmol."},{"key":"22758_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12886-020-01508-8","volume":"20","author":"K Kashiwagi","year":"2020","unstructured":"Kashiwagi, K., Chono, E., Koesters, S. & Yap, P. S. Persistence and treatment patterns of fixed combination drugs for glaucoma: a retrospective claims database study in Japan. BMC Ophthalmol. 20, 223 (2020).","journal-title":"BMC Ophthalmol."},{"key":"22758_CR28","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s10384-023-01020-8","volume":"67","author":"K Kashiwagi","year":"2023","unstructured":"Kashiwagi, K., Ouchi, K., Shibasaki, Y. & Suginaka, M. Persistence of the carteolol hydrochloride\/latanoprost fixed-combination ophthalmic solution, compared with the other \u03b2-blocker\/prostanoid FP receptor agonist fixed-combination ophthalmic solutions. Jpn J. Ophthalmol. 67, 658\u2013667 (2023).","journal-title":"Jpn J. Ophthalmol."},{"key":"22758_CR29","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s10384-021-00868-y","volume":"65","author":"M Aihara","year":"2021","unstructured":"Aihara, M., Lu, F., Kawata, H., Iwata, A. & Odani-Kawabata, N. Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study. Jpn J. Ophthalmol. 65, 810\u2013819 (2021).","journal-title":"Jpn J. Ophthalmol."},{"key":"22758_CR30","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s10384-020-00748-x","volume":"64","author":"M Aihara","year":"2020","unstructured":"Aihara, M. et al. Intraocular pressure-lowering effect of omidenepag isopropyl in Latanoprost non-\/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study. Jpn J. Ophthalmol. 64, 398\u2013406 (2020).","journal-title":"Jpn J. Ophthalmol."},{"key":"22758_CR31","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.2147\/OPTH.S465369","volume":"18","author":"TH Wang","year":"2024","unstructured":"Wang, T. H. et al. Omidenepag isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma\/Ocular hypertension: the randomized phase III PEONY trial. Clin. Ophthalmol. 18, 2093\u20132106 (2024).","journal-title":"Clin. Ophthalmol."},{"key":"22758_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ajo.2024.02.010","volume":"263","author":"J Bacharach","year":"2024","unstructured":"Bacharach, J. et al. Omidenepag isopropyl versus timolol in patients with glaucoma or ocular hypertension: two randomized phase 3 trials (SPECTRUM 4 and 3). Am. J. Ophthalmol. 263, 23\u201334 (2024).","journal-title":"Am. J. Ophthalmol."},{"key":"22758_CR33","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1097\/IJG.0000000000002321","volume":"32","author":"JF Panarelli","year":"2023","unstructured":"Panarelli, J. F. et al. Omidenepag isopropyl in Latanoprost Low\/Nonresponders with primary open angle glaucoma or ocular hypertension: A phase 3, Nonrandomized, Two-Phase, open-Label study. J. Glaucoma. 32, 999\u20131005 (2023).","journal-title":"J. Glaucoma"},{"key":"22758_CR34","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s12325-021-02035-8","volume":"39","author":"T Nakazawa","year":"2022","unstructured":"Nakazawa, T., Takahashi, K., Kuwayama, Y., Nomura, A. & Shimada, F. Interim results of Post-Marketing observational study of omidenepag isopropyl for glaucoma and ocular hypertension in Japan. Adv. Ther. 39, 1359\u20131374 (2022).","journal-title":"Adv. Ther."},{"key":"22758_CR35","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s10384-024-01052-8","volume":"68","author":"K Inoue","year":"2024","unstructured":"Inoue, K. et al. Three-year efficacy and safety of omidenepag isopropyl in patients with normal tension glaucoma. Jpn J. Ophthalmol. 68, 206\u2013210 (2024).","journal-title":"Jpn J. Ophthalmol."},{"key":"22758_CR36","unstructured":"Santen Pharmaceutical Co. Ltd. EYBELIS\u00ae ophthalmic solution \/ EYBELIS\u00ae mini ophthalmic solution package insert. Revis. May (2022)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22758-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22758-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22758-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:13:55Z","timestamp":1781612035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22758-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22758"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-22758-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was funded by Santen Pharmaceutical Co., Ltd.K. Kashiwagi has received consulting fees from Santen Pharmaceutical Co., Ltd.T. Nakano has received consulting fees from Santen Pharmaceutical Co., Ltd.T. Nakazawa has received consulting fees from Santen Pharmaceutical Co., Ltd.M. Fuwa., N. Otsuka, D. Shii, and R. Miyahara are employees of Santen Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38869"}}